ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma is listed on Nasdaq Stockholm main market (small cap) under the ticker ACE

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• November 8 @ 08:00

  Ascelia Pharma interim report Q1 (Jul-Sep 2019) for fiscal year 2019/2020

• November 14 @ 10:00 - 12:00

  Ascelia Pharma Annual General Meeting

• November 22

  Redeye Life Science Day

• 2019-08-22Phase III study of Mangoral to start in H2-2019
• 2019-08-20Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019
• 2019-06-10Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product
• 2019-05-23Presentation from Avanza share day
• 2019-05-20Ascelia Pharma to present at Avanza börsdag, 22 May 2019